## Glaucoma

# Systemic Alpha1-Adrenoceptor Antagonists and Increased Risk of Open-Angle Glaucoma: A Nationwide Population-Based Cohort Study

Hong-Zin Lin,[1,2] Tsung-Cheng Hsieh,[2] Jung-Lun Wu,[2] Ming-Shan He,[1] and Yuan-Chieh Lee[1–3]

[1]Department of Ophthalmology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan
[2]Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan
[3]Department of Ophthalmology and Visual Science, Tzu Chi University, Hualien, Taiwan

Correspondence: Yuan-Chieh Lee, Department of Ophthalmology, Buddhist Tzu Chi General Hospital, Tzu Chi University, No. 707, Sec. 3 Chung-Yung Road, Hualien, 970 Taiwan;
yuanchieh.lee@gmail.com.

H-ZL and T-CH contributed equally to the work presented here and should therefore be regarded as equivalent authors.

**PURPOSE.** To examine the risk of open-angle glaucoma (OAG) among patients receiving alpha1-adrenoceptor ($\alpha$1-AR) antagonists for lower urinary tract symptoms (LUTS).

**METHODS.** This was a nationwide, population-based, retrospective cohort study from Asia/Taiwan. One million beneficiaries were randomly sampled from among 27.38 million individuals enrolled in the National Health Insurance program, and subjects with a diagnosis of LUTS from 2001 to 2012 were identified ($N = 105,341$). After 1:1 propensity score matching by gender, age, comorbid medical diseases, number of all medical visits during the observational period, and index date, 4081 patients were enrolled in the study group, comprised of patients who had taken $\alpha$1-AR antagonists, and 4081 patients were enrolled in the control group, comprised of patients who had never taken $\alpha$1-AR antagonists. The incidence and risk of OAG (defined as two ambulatory visits with a ICD-9 diagnosis code 365, excluding ICD-9 diagnosis codes 365.2–365.6, 365.02, 365.03, 365.13, 365.14, and 365.8) were calculated.

**RESULTS.** Patients taking $\alpha$1-AR antagonists had a higher incidence ratio of 1.86 (95% confidence interval [CI], 1.30–2.65) for developing OAG. After adjusting for age, gender, and comorbidities, the hazard ratio (HR) for OAG for patients taking $\alpha$1-AR antagonists was 1.66 (95% CI, 1.16–2.39; $P = 0.006$). Among patients with hypertension, the hazard ratio for OAG associated with taking $\alpha$1-AR antagonists increased to 1.79 (95% CI, 1.07–2.99; $P = 0.003$). On the other hand, the association of $\alpha$1-AR antagonists with OAG was not significant among patients with diabetes mellitus, hyperlipidemia, or older age.

**CONCLUSIONS.** The findings of our study suggest an increased risk for OAG among patients taking $\alpha$1-AR antagonists for LUTS, especially in patients with hypertension.

Keywords: alpha-adrenoceptor antagonists, open-angle glaucoma, hypertension, ocular perfusion pressure, lower urinary tract symptoms

G laucoma is the leading cause of irreversible blindness. It has been estimated that the number of people with glaucoma worldwide will increase to 111.8 million in 2040.[1] Investigation of the risk factors is essential for the prevention and treatment of glaucoma. Low ocular perfusion pressure (OPP) and hypoperfusion of the optic nerve head (ONH) are important mechanisms of glaucoma[2–5] that could be caused by systemic medications.

With aging of the worldwide population, lower urinary tract symptoms (LUTS) have become highly prevalent,[6] and alpha1-adrenoceptor ($\alpha$1-AR) antagonists rank among the primary treatments for LUTS.[7] $\alpha$1-AR antagonists decrease tone in the smooth muscle of the bladder neck and prostate, thus improving urinary flow. The adverse effects of $\alpha$1-AR antagonists include asthenia, nasal congestion, dizziness, orthostatic hypotension, and intraoperative floppy iris syndrome (IFIS).[7] Dizziness and orthostatic hypotension

suggest impairment of dynamic cerebral perfusion. Because ocular circulation shares a similar blood supply with cerebral flow, impaired cerebral perfusion might imply insufficient ocular perfusion. By using a nationwide, population-based dataset from Taiwan, this study investigated the relationship between $\alpha$1-AR antagonists for LUTS and the risk of open-angle glaucoma (OAG).

## MATERIALS AND METHODS

### Database

The National Health Insurance Research Database (NHIRD) contains registration files and original claims data for 27.38 million individuals. We randomly sampled the NHIRD registration data for 1 million individuals who were registered in the National Health Insurance program from

January 1, 2000, to December 31, 2012. All data in the database are encrypted to protect the privacy of individuals. The database provides detailed outpatient and inpatient claims data including patient identification number; birth date; sex; diagnostic codes according to the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM); treatment information; medical costs; dates of admission and discharge; and date of death. All datasets are interlinked through the patient identification number.

### Study Design

This study was approved by the Ethics Committee and Human Subjects Institutional Review Board of Tzu Chi Hospital, Hualien, Taiwan. This retrospective cohort study was comprised of insured patients seeking ambulatory care between January 1, 2001, and December 31, 2012, and who received a diagnosis of bladder neck obstruction (ICD-9 code 596.0), neurogenic bladder (ICD-9 code 596.5, excluding 596.53 and 596.55), spastic urethral sphincter (ICD-9 code 599.84), benign prostate hyperplasia (ICD-9 code 600), stress urinary incontinence (ICD-9 code 625.6), dysuria (ICD-9 code 788.1), urinary retention (ICD-9 code 788.2), urinary incontinence (ICD-9 code 788.3), or frequency of urination and polyuria (ICD-9 code 788.4) ($N = 105,341$). The dates of patients receiving their first prescriptions of $\alpha$1-AR antagonists (including phenoxybenzamine, terazosin, doxazosin, tamsulosin, and silodosin) were assigned as the index dates in the study group, and the dates of diagnosis of the above diseases were assigned as the index dates in the control group. The follow-up period of each subject was defined as the time interval from the index date to the last observation day. Subjects with OAG were defined as individuals who had two ambulatory visits from the index date with a diagnosis code of glaucoma (ICD-9 code 365), excluding primary angle-closure glaucoma (ICD-9 code 365.2), anatomical narrow angle borderline glaucoma (ICD-9 code 365.02), pigmentary open-angle glaucoma (ICD-9 code 365.13), glaucoma of childhood (ICD-9365.14), corticosteroid-induced glaucoma (ICD-9 code 365.3), steroid responders borderline glaucoma (ICD-9 code 365.03), glaucoma associated with congenital anomalies dystrophies and systemic syndromes (ICD-9 code 365.4), glaucoma associated with disorders of the lens (ICD-9 code 365.5), glaucoma associated with other ocular disorders (ICD-9 code 365.6), and other specified forms of glaucoma (ICD-9 code 365.8). The study excluded patients younger than 18 years of age or older than 70 years of age, as well as those with use of drugs for LUTS other than $\alpha$1-AR antagonists (mainly anticholinergics and tricyclic antidepressants), with use of $\alpha$1-AR antagonists for an unknown period or before the diagnosis of the above diseases, with an interval from the first diagnosis date of LUTS to starting $\alpha$1-AR antagonists of more than 15 days, and with a previous diagnosis of OAG or angle-closure glaucoma prior to their index date.

Initially, the study group was comprised of 11,765 patients who received their first prescription of $\alpha$1-AR antagonists between January 1, 2001, and December 31, 2012, and the control group was comprised of 18,273 patients who had the above diagnosis but had not received any medication. Both groups were selected by a 1:1 propensity score matching for age; gender; Charlson Comorbidity Index (CCI) scores and comorbid medical diseases including diabetes mellitus, hypertension, hyperlipidemia, chronic heart disease, and chronic renal disease; number of all medical visits during the follow-up period; and index date. After matching, 4081 patients were enrolled in the study group and 4081 patients were enrolled in the control group. The data flow for the study is illustrated in Figure 1.

## STATISTICAL ANALYSIS

All statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA). Patient demographics were compared using standardized differences that reflect the mean difference as a percentage of the standard deviation (SD), as described by Mamdani et al.[8] A standardized difference measure is less sensitive to sample size than traditional hypothesis tests and estimates the relative magnitude of differences. The demographic variables with a standard difference of >0.1 between the study group and the control group were considered clinically meaningful differences. The 1000 person-year incidence of OAG with or without taking $\alpha$1-AR antagonists, defined as $1000 \times$ (number of newly diagnosed OAG)/(total follow-up years of the subjects), and their incidence ratios were calculated. The Kaplan–Meier estimator was used to examine the differences in OAG-free survival rates between the study and the control cohorts (time zero = index date). Competing risk regression was used to estimate the adjusted hazard ratio (HR) and 95% confidence interval (CI) for OAG, adjusting for age, gender, and comorbidities, including CCI scores, diabetes mellitus, hypertension, hyperlipidemia, chronic heart disease, and chronic renal disease. $P < 0.05$ was considered significant.

## RESULTS

The demographic characteristics and comorbidities for the study and control cohorts are presented in Table 1. The mean age of the study patients, gender, comorbidities (CCI scores, diabetes mellitus, hypertension, hyperlipidemia, chronic heart disease, and chronic renal disease), number of visits during the follow-up period, and mean follow-up period were well matched between the two groups, with all standardized differences being 0.02 or lower.

The incidence of OAG diagnosis per 1000 person-years was 3.77 (95% CI, 2.97–4.57) for the study group and 2.03 (95% CI, 1.44–2.62) for the control group. Patients taking $\alpha$1-AR antagonists had a significantly higher incidence of OAG, with an incidence ratio of 1.86 (95% CI, 1.30–2.65). After adjusting for age, gender, and comorbidities, the OAG HR for subjects taking $\alpha$1-AR antagonists was 1.66 (95% CI, 1.16–2.39; $P = 0.006$) (Table 2). Kaplan–Meier survival analysis showed that patients taking $\alpha$1-AR antagonists had significantly lower OAG-free survival rates than the controls during the follow-up period (Fig. 2). The competing risk regression analysis showed that the HR for OAG was 1.76 (95% CI, 1.15–2.69, $P = 0.009$) for patients with hyperlipidemia relative to those without hyperlipidemia. Age, gender, CCI scores, diabetes mellitus, hypertension, chronic heart disease, and chronic renal disease did not influence the development of OAG (Table 2).

Table 3 provides details regarding OAG and the use of $\alpha$1-AR antagonists among patients older than 50 years of age with comorbid diabetes mellitus, hypertension, or hyperlipidemia. Among patients older than 50, the hazard ratio for OAG and the use of $\alpha$1-AR antagonists was 1.40 (95% CI, 0.90–2.19; $P = 0.14$) compared to those not taking $\alpha$1-AR antagonists, indicating that the risk was not

```
┌─────────────────────────────────────────────┐
│ LUTS patients from Jan 1st, 2000 to Dec 31th, 2012. │
│                  105,341                      │
└─────────────────────────────────────────────┘
```

Exclude

**51772** use of drugs for LUTS other than α1-AR antagonists or α1-AR antagonists usage for unknown period

**9628** Use α1-AR antagonists prior to diagnosis of the above diseases

**1368** OAG or ACG prior to their index date

**2268** < 18 y/o

**3935** Interval from the initial date of LUTS to drug used over 15 days

**141** OAG after cataract surgery

**6191** > 70 y/o

```
┌─────────────────────────────────────────────┐
│ LUTS patients from Jan 1st, 2000 to Dec 31th, 2012. │
│                  30038                        │
└─────────────────────────────────────────────┘
```

```
┌──────────────────────┐          ┌──────────────────────┐
│ α1-AR antagonists use │          │ Without               │
│        11,765         │          │ α1-AR antagonists use │
│                       │          │        18273          │
└──────────────────────┘          └──────────────────────┘
```

1:1 propensity score matching*

```
┌──────────────────────┐          ┌──────────────────────┐
│ α1-AR antagonists use │          │ Without               │
│        4,081          │          │ α1-AR antagonists use │
│                       │          │        4,081          │
└──────────────────────┘          └──────────────────────┘
```

*1:1 propensity score matching by age, gender, diabetes mellitus, hypertension, hyperlipidemia, chronic heart disease, chronic renal disease, number of visits and duration from the index date.

**FIGURE 1.** Study protocol and profile. y/o, years old.

**TABLE 1.** Demographics of Patients Taking and Not Taking α1-AR Antagonists for LUTS

| Demographic | Patients Receiving α1-AR Antagonists ($N = 4081$) | Comparison Patients ($N = 4081$) | Standard Difference |
|---|---|---|---|
| Age, mean ± SD | 50.5 ± 10.0 | 50.4 ± 10.0 | 0.01 |
| <50 y, $n$ (%) | 1917 (47) | 1927 (47.2) | 0.00 |
| ≥50 y, $n$ (%) | 2164 (53) | 2154 (52.8) | |
| Sex | | | |
| Male, $n$ (%) | 3719 (91.1) | 3715 (91) | 0.00 |
| Female, $n$ (%) | 362 (8.9) | 366 (9) | |
| CCI score | 2.8 ± 2.0 | 2.8 ± 2.0 | 0.01 |
| ≤3, $n$ (%) | 2063 (50.6) | 2054 (50.3) | 0.00 |
| >3, $n$ (%) | 2018 (49.4) | 2027 (49.7) | |
| Diabetes mellitus, $n$ (%) | 912 (22.3) | 905 (22.2) | 0.00 |
| Hypertension, $n$ (%) | 1611 (39.5) | 1586 (38.9) | 0.01 |
| Hyperlipidemia, $n$ (%) | 1534 (37.6) | 1537 (37.7) | 0.00 |
| Chronic heart disease, $n$ (%) | 761 (18.6) | 754 (18.5) | 0.00 |
| Chronic renal disease, $n$ (%) | 514 (12.6) | 489 (12) | 0.02 |
| Number of medical visits, mean ± SD | 121.1 ± 118.9 | 121.4 ± 121.4 | 0.00 |
| Follow-up period (y), mean ± SD | 5.5 ± 3.5 | 5.6 ± 3.6 | 0.01 |

significant. Among patients with comorbid diabetes mellitus, the hazard ratio for OAG and the use of α1-AR antagonists was 1.64 (95% CI, 0.85–3.15) compared to those not taking α1-AR antagonists, again indicating that the risk was not

significant ($P = 0.14$). However, among patients with comorbid hypertension, the hazard ratio for OAG and the use of α1-AR antagonists was 1.79 (95% CI, 1.07–2.99, $P = 0.03$) by competing risks regression analysis. Among patients with

**FIGURE 2.** Kaplan–Meier survival curves for OAG-free survival for patients using and not using $\alpha$1-AR antagonists for LUTS in the general population.

**TABLE 2.** Adjusted Hazard Ratios for OAG and Factors Relative to Their Controls

| Variable | Competing Risks Regression | |
| --- | --- | --- |
| | HR (95% CI) | P |
| $\alpha$1-AR antagonists | 1.66 (1.16–2.39) | 0.006 |
| Older age ($\geq$50 y) | 1.33 (0.83–2.15) | 0.236 |
| Gender (female) | 0.81 (0.40–1.65) | 0.559 |
| CCI score (>3) | 1.04 (0.65–1.66) | 0.872 |
| Diabetes mellitus | 1.09 (0.71–1.67) | 0.702 |
| Hypertension | 1.13 (0.75–1.69) | 0.560 |
| Hyperlipidemia | 1.76 (1.15–2.69) | 0.009 |
| Chronic heart disease | 1.53 (1.01–2.34) | 0.046 |
| Chronic renal disease | 0.85 (0.52–1.40) | 0.532 |

**TABLE 3.** Hazard Ratios for OAG and $\alpha$1-AR Antagonist Usage for LUTS in Older Patients with Comorbid Diabetes Mellitus, Hypertension, or Hyperlipidemia

| Comorbidity | Competing Risks Regression | |
| --- | --- | --- |
| | HR (95% CI) | P |
| Age $\geq$ 50 y | 1.40 (0.90–2.19) | 0.14 |
| Diabetes mellitus | 1.64 (0.85–3.15) | 0.14 |
| Hypertension | 1.79 (1.07–2.99) | 0.03 |
| Hyperlipidemia | 1.43 (0.90–2.29) | 0.13 |

comorbid hyperlipidemia, taking $\alpha$1-AR antagonists did not increase the risk of OAG. The Kaplan–Meier curves of each subgroup are displayed in Figure 3.

## DISCUSSION

In this population-based, retrospective cohort study in which the data for 4081 patients prescribed $\alpha$1-AR antagonists and data for 4081 control subjects were analyzed, we found that patients taking $\alpha$1-AR antagonists had a significantly higher incidence ratio of 1.86 (95% CI, 1.30–2.65)

for developing OAG in the follow-up period. The adjusted hazard ratio for OAG and $\alpha$1-AR antagonist use was 1.66 (95% CI, 1.16–2.39; $P = 0.006$). The hazard ratio increased to 1.79 (95% CI, 1.07–2.99; $P = 0.003$) in hypertensive patients. Diabetes mellitus, hyperlipidemia, and older age did not add to the risk of OAG in patients taking $\alpha$1-AR antagonists.

In the current study, the competing risks regression approach was applied for analyzing the risk of $\alpha$1-AR antagonist rather than the traditional Cox proportional model, because the rate of mortality during the follow-up period in the current study ($\alpha$1-AR antagonist group: 316/4081, or 7.7%; comparison group: 260/4081, or 6.4%) was much higher than the rate of OAG ($\alpha$1-AR antagonist group: 86/4081, or 2.1%; comparison group: 46/4081, or 1.1%). The impact of competing events (e.g., mortality) might be significant. When competing events such as mortality may preclude the occurrence or may substantially alter the study outcome (OAG in the current study), competing risks regression is the better approach.

The effects of $\alpha$1-AR antagonists on glaucoma are interesting. Several topically applied $\alpha$1-AR antagonists were reported to have an intraocular pressure (IOP)-lowering effect.[9–16] Bunazosin hydrochloride, a selective $\alpha$1-AR antagonist used systemically as an antihypertensive drug, has been reported to reduce IOP when applied topically in monkeys by increasing uveoscleral outflow from ciliary muscle relaxation.[9] It is generally believed that lower IOP reduces the risk of glaucoma progression.[10] However, our study showed that systemic administration of $\alpha$1-AR antagonists for LUTS was associated with an increased risk for OAG. The disparity might come from different study species or population, or different routes of drug administration. Although topically applied $\alpha$1-AR antagonists have some IOP-lowering effect, the effect of systemically applied $\alpha$1-AR antagonists on IOP has not yet been determined.

Intraoperative floppy iris syndrome is a notorious ocular complication of $\alpha$1-AR antagonist use for LUTS, with a high rate of incidence ranging from 19% to 52% during cataract

**FIGURE 3.** Kaplan–Meier survival curves for OAG-free survival for patients using and not using $\alpha$1-AR antagonists. (A) Patients $\geq$ 50 years old. (B) Patients with diabetes mellitus. (C) Patients with hypertension. (D) Patients with hyperlipidemia.

surgery.[11,12] Morphologic changes, including small pupil diameter, iris stromal thinning, and depigmentation, have been described in IFIS eyes.[13] Pathological changes including iris dilator muscle atrophy and vacuolation, uneven iris pigment granules, and lipofuscin-like granules have also been found in IFIS.[14] $\alpha$1-AR has been found in iris dilator smooth muscle and iris arteriole and may participate in IFIS development. We know that some of the ciliary muscle fibers attach to the scleral spur, and their contraction increases aqueous outflow by opening up the spaces of the trabecular meshwork. If $\alpha$1-AR antagonists cause atrophy and vacuolation of not only the iris dilator muscle but also the ciliary muscle fibers, then increased IOP may be anticipated and hence development of OAG. However, this hypothesis remains unproven and requires further investigation.

Topical application of $\alpha$1-AR antagonists either does not affect or minimally affects blood pressure (BP),[15] whereas systemic administration of all kinds of $\alpha$1-AR antagonists for LUTS reduces systolic and diastolic BP by approximately 10%.[16–20] The vascular theory is considered one of the contributors to pathogenesis of OAG, especially in normal-tension glaucoma. Ocular perfusion pressure (OPP) is the difference between the mean arterial pressure and IOP. Due to the complex interactions among BP, IOP, and OPP, the association between BP and glaucoma remains controversial. Several studies have reported a higher risk of OAG in patients with hypertension.[2,21,22] The proposed pathophysiologic mechanisms include higher IOP associated with more elevated BP,[2,21] microvascular damage, increased vascular resistance, and impaired ocular perfusion to the optic nerve caused by sustained hypertension.[2,22] In contrast, other studies have reported that low BP can lead to low OPP and has been associated with new glaucoma development or with a progression of established glaucoma.[2–5,23]

Bonomi et al.[2] showed that the prevalence of glaucoma increased inversely with diastolic OPP. Leske et al.[3] reported that reduced baseline BP (systolic BP < 101, diastolic BP < 55, or mean BP < 42 mm Hg) was associated with a threefold increased risk of developing OAG. The Barbados Eye Study showed that lower systolic BP and lower OPP doubled the risk of developing glaucoma.[5] In the Los Angeles Latino Eye Study, high systolic BP and mean BP, low diastolic BP, and low diastolic OPP, systolic OPP, and mean OPP were associated with increased risk of OAG.[23] Also, nocturnal arterial hypotension was found to play a critical role in the pathogenesis of glaucomatous optic neuropathy.[24–28] Most healthy people have a dip of 10% to 20% in nocturnal BP compared to daytime BP; however, others present extreme dipping (>20% dipping of nocturnal BP compared to daytime BP) or reverse dipping of BP.[29–31] In the Maracaibo Aging Study, extreme nighttime dipping of systolic pressure or diastolic pressure was a significant risk factor (odds ratios 19.78 and 5.55, respectively) for glaucomatous damage.[28] Charlson et al.[32] found that glaucoma progression was associated with the duration and magnitude of nocturnal BP reduction, especially with a decrease of more than 10 mm Hg. The rates of visual field progression were highest (24%) in extreme dippers in normal-tension glaucoma in a 3-year follow-up study.[27] We speculate that the

association between $\alpha$1-AR antagonists for LUTS and OAG might be partially due to their BP-lowering effect and hence decreased OPP. For those dippers and extreme dippers, taking $\alpha$1-AR antagonists might cause a further decline of nocturnal BP to a critical point below which autoregulation of the ONH would lose its effect. If this is true, use of a 24-hour ambulatory BP monitor by patients taking $\alpha$1-AR antagonists should perhaps be considered in order to adjust the $\alpha$1-AR antagonist prescription accordingly. Taking $\alpha$1-AR antagonists in the daytime, taking a minimum dose, and avoiding bedtime dosing may alleviate the risk; however, these suggested precautions require further study.

We found that the hazard ratio for OAG and the use of $\alpha$1-AR antagonists for LUTS increased to 1.79 in hypertensive patients. Autoregulation of the ONH is disrupted in low BP,[33] especially in those with older age and chronic hypertension.[34] In the Early Manifest Glaucoma Trial, a lower systolic OPP increased the risk of glaucoma progression (HR = 1.55) in patients with higher baseline IOP.[4] In hypertensive patients with impaired autoregulation, a decreased OPP caused by the BP-lowering effect of $\alpha$1-AR antagonists would cause more damage to the ONH and increase the risk of glaucoma.

Our study has several strengths. First, the NHIRD provided population-based and representative claims information for insured people in Taiwan and reduced selection bias. Second, the large sample size and longitudinal study design provided enough statistical power to detect differences between the study group and control cohorts. Third, the NHIRD contains all claims data that were recorded electronically, ensuring accuracy and avoiding recall bias.

This study has several limitations. First, the study used data retrieved from NHIRD, which lacks strict disease definitions for LUTS and glaucoma. Second, patients in this retrospective study did not receive a thorough ocular exam and might not have been free of glaucoma before the index day. The enrolled patients also did not receive regular ocular examinations; hence, glaucoma might be delayed or underdiagnosed. Such inaccuracy, however, existed similarly in both the study group and the control group; an extended period of observation might help compensate for that inaccuracy. Because the difference in the incidence of glaucoma persisted during the 12-year observation period (Figs. 2, 3), that difference should be accurate. Third, there were no data for BP or IOP in the NHIRD, let alone OPP or its circadian variation; thus, further exploration into these associations is lacking. Fourth, the database could not provide other clinical ocular details that were related to glaucoma development, such as refractive error, axial length, status of the lens, nerve fiber thickness, or progression of the visual field. Investigations into the pathophysiological mechanism are limited. Fifth, information regarding some of the potential risk factors for glaucoma could not be obtained, such as drinking, smoking habits, personal lifestyle, occupation, or the severity of comorbid diseases. Finally, most of the study subjects in the current study were ethnically Chinese people, and the study results might not apply to other races.

In conclusion, to the best of our knowledge, this population-based study is the first to determine that patients taking $\alpha$1-AR antagonists for LUTS have a higher risk for OAG, especially among those with hypertension. A more detailed understanding of the possible pathogenesis of glaucoma with $\alpha$1-AR antagonists for LUTS awaits future studies.

## References

1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121:2081–2090.

2. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. *Ophthalmology*. 2000;107:1287–1293.

3. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. *Arch Ophthalmol*. 2002;120:954–959.

4. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. *Ophthalmology*. 2007;114:1965–1972.

5. Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. *Arch Ophthalmol*. 1995;113:918–924.

6. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU Int*. 2011;108:1132–1138.

7. Strittmatter F, Gratzke C, Stief CG, Hedlund P. Current pharmacological treatment options for male lower urinary tract symptoms. *Expert Opin Pharmacother*. 2013;14:1043–1054.

8. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. *BMJ*. 2005;330:960–962.

9. Akaishi T, Takagi Y, Matsugi T, Ishida N, Hara H, Kashiwagi K. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. *J Glaucoma*. 2004;13:312–318.

10. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol*. 2003;121:48–56.

11. Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. *Am J Ophthalmol*. 2007;143:150–151.

12. Keklikci U, Isen K, Unlu K, Celik Y, Karahan M. Incidence, clinical findings and management of intraoperative floppy iris syndrome associated with tamsulosin. *Acta Ophthalmol*. 2009;87:306–309.

13. Prata TS, Palmiero PM, Angelilli A, et al. Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome. *Ophthalmology*. 2009;116:877–881.

14. Goseki T, Shimizu K, Ishikawa H, et al. Possible mechanism of intraoperative floppy iris syndrome: a clinicopathological study. *Br J Ophthalmol*. 2008;92:1156–1158.

15. Kanno M, Araie M, Koibuchi H, Masuda K. Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. *Br J Ophthalmol*. 2000;84:293–299.

16. Benfey BG. Cardiovascular actions of phenoxybenzamine. *Br J Pharmacol Chemother*. 1961;16:6–14.

17. Elliott HL, Meredith PA, Sumner DJ, McLean K, Reid JL. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. *Br J Clin Pharmacol*. 1982;13:699–703.

18. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. *Eur Urol*. 1998;33:481–488.

19. Cho HJ, Yoo TK. Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability. *Res Rep Urol*. 2014;6:113–119.

20. Lee SH, Park KK, Mah SY, Chung BH. Effects of $\alpha$-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. *Prostate Cancer Prostatic Dis*. 2010;13:333–337.

21. Dielemans I, Vingerling JR, Algra D, Hofman A, Grobbee DE, de Jong PT. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. *Ophthalmology*. 1995;102:54–60.

22. Mitchell P, Lee AJ, Rochtchina E, Wang JJ. Open-angle glaucoma and systemic hypertension: the Blue Mountains Eye Study. *J Glaucoma*. 2004;13:319–326.

23. Memarzadeh F, Ying-Lai M, Chung J, Azen SP, Varma R, Los Angeles Latino Eye Study Group. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci*. 2010;51:2872–2877.

24. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. *Am J Ophthalmol*. 1994;117:603–624.

25. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. *Surv Ophthalmol*. 1999;43(suppl 1):S10–S16.

26. Bowe A, Grünig M, Schubert J, et al. Circadian variation in arterial blood pressure and glaucomatous optic neuropathy–a systematic review and meta-analysis. *Am J Hypertens*. 2015;28:1077–1082.

27. Kwon J, Lee J, Choi J, Jeong D, Kook MS. Association between nocturnal blood pressure dips and optic disc hemorrhage in patients with normal-tension glaucoma. *Am J Ophthalmol*. 2017;176:87–101.

28. Melgarejo JD, Lee JH, Petitto M, et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo Aging Study. *Ophthalmology*. 2018;125:807–814.

29. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. *Lancet*. 1988;2:397.

30. Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. *J Hypertens Suppl*. 1991;9:S42–S44.

31. Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. *Adv Drug Deliv Rev*. 2007;59:904–922.

32. Charlson ME, de Moraes CG, Link A, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. *Ophthalmology*. 2014;121:2004–2012.

33. Riva CE, Hero M, Titze P, Petrig B. Autoregulation of human optic nerve head blood flow in response to acute changes in ocular perfusion pressure. *Graefes Arch Clin Exp Ophthalmol*. 1997;235:618–626.

34. Prada D, Harris A, Guidoboni G, Siesky B, Huang AM, Arciero J. Autoregulation and neurovascular coupling in the optic nerve head. *Surv Ophthalmol*. 2016;61:164–186.